The role of inflammation in stress cardiomyopathy by Ciutac, Andra Maria & Dawson, Dana
 
1 











Dana Dawson, DM, FRCP, D.Phil, FESC 
Professor of Cardiovascular Medicine and Consultant Cardiologist 
 
Corresponding Author’s Institution: 
School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, 
Foresterhill, Aberdeen, Scotland, United Kingdom 
 















Stress cardiomyopathy (SC) is an increasingly recognised form of acute heart failure, 
which has been linked to a wide variety of emotional and physical triggers. The 
pathophysiological mechanisms of the disease remain incompletely understood, 
however, inflammation has been recently shown to play a pivotal role. This review 
summarises the most notable findings of myocardial inflammation, demonstrated 
from biopsies and cardiac magnetic resonance imaging in humans. In the acute 
stage macrophage infiltration appears to represent the substrate for myocardial 
oedema, together defining the local myocardial inflammation. This appears to evolve 
into a low grade systemic chronic inflammation which could explain the protracted 
clinical course of these patients and raises hope for finding a specific SC cardiac 
biomarker as well as a therapeutic breakthrough.   As a parallel to the human 
findings the review covers some of the emerging mechanistic insights from 
experimental models, which, albeit not proven in the human condition, highlight the 
possible importance in pursuing distinct paths of investigation such as the beta-
receptor signaling, aberrations of nitric oxide generation and signaling and the 
contribution of the vascular endothelium/permeability to oedema and inflammation 











Acute stress cardiomyopathy (SC), also known as takotsubo cardiomyopathy, is an 
acute heart failure syndrome, first noticed in 1990 by Sato in Japan. [1] The eponym 
of “takotsubo” refers to an octopus trap used by Japanese fishermen and alludes to 
the typical shape of the left ventricle in this syndrome, consisting of a dyskinetic apex 
and relatively hyperkinetic base. However, since the first description of the disease 
more types of SC have been identified:  basal, mid-ventricular and focal subtypes. 
SC has initially been diagnosed more commonly in middle-aged and elderly women, 
thought to represent ~ 90% of the cases, although the condition is increasingly seen 
in women of all ages as well as men. [2] The hallmark of this cardiomyopathy is 
being precipitated by a stressor event, either of an emotional or physical nature (or 
sometimes combined). Clinically, it presents similarly to acute coronary syndromes 
with chest pain, breathlessness, ECG changes (ST- elevation, T wave changes) and 
only mildly-moderately elevated cardiac biomarkers. However, unlike myocardial 
infarction, coronary angiography shows no acute coronary thrombosis, making this 
the most notable contributor in the differential diagnosis (Mayo Clinic; European 
Cardiology Society criteria) [3, 4]. Approximately 2-3% of the initially suspected acute 
coronary syndromes patients are in fact sufferers of SC. [5] Cardiac imaging shows 
that the left ventricular dysfunction usually extends beyond the territory of a single 
coronary artery. While the left ventricular ejection fraction and regional dyskinesia 
recover within days to weeks, other parameters such as echocardiography derived 
global longitudinal strain or apical twist have shown to remain decreased over 
months after the acute episode. [6] This contradicts the initial view according to 
which SC is a transient and fully reversible disease. Although an acute, in-hospital 
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mortality rate of 4-5% has been recognised, it is relatively recent that registry-derived 
data reported relatively high long-term rates of major adverse cardiac and 
cerebrovascular events, which are comparable to those seen after acute coronary 
syndromes. [7]  
It follows therefore, that the pathological processes occurring within the left 
ventricular myocardium are of significant importance and directly contribute towards 
this guarded prognosis. This review will describe the current knowledge on the 
myocardial inflammatory processes in SC and analyses how these may contribute to 
the recovery and outcomes in the aftermath of an acute episode. Where possible, 
these will be correlated with currently available data from myocardial biopsies, 
imaging (cardiac magnetic resonance) and systemic inflammatory processes. 
Finally, reference to some of the most relevant experimental work will be made, to 
highlight possible avenues of further investigation with the caveat that the 
experimental models of SC are simplistic compared to the much more complex 
human syndrome. 
CARDIAC IMAGING 
Whilst echocardiography remains the cornerstone of cardiac imaging in routine 
clinical care, cardiac magnetic resonance (CMR) imaging has specific application in 
SC, as it is additive to the information already obtained [8].  
Firstly, CMR is able to rule out a myocardial infarction (MI) in SC. Whilst rare 
occurrences of fibrosis have been reported, the characteristic pattern of myocardial 
fibrosis that is diagnostic of a MI is absent in SC: the dense myocardial fibrosis seen 
in MI seen as late gadolinium enhancement and located subendocardially or 
transmurally is absent in SC [9].  
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Secondly, CMR is better able to offer an appreciation of the extent of the wall motion 
abnormality, being also the gold standard for right ventricular imaging. As a result, 
cardiac MRIs have also unexpectedly revealed a substantial right ventricular 
involvement, resulting in biventricular ballooning. Approximately 40-50% of cases 
have right ventricular dysfunction concomitantly present, which was associated with 
a longer hospitalization period and increased rate of complications. [10] Moreover, 
cine CMR sequences are used to underline the overall contraction abnormalities, 
consisting usually of anterior, antero- lateral and antero-septal walls dyskinesia, 
alongside a hyperkinetic base. The atypical forms are also well identified on CMR: 
basal (inverted), mid-ventricular and especially the focal one.  
Further on, 31P-magnetic resonance spectroscopy has revealed a major impairment 
in the energetic status both acutely and after period of 3-5 months (decreased 
PCr/-ATP ratio). [8] The cardiomyocyte adaptability to the decreased energy 
production is reflected in the increased expression of survival pathways seen from 
myocardial biopsies: upregulation of Phosphoinositide 3-kinases (PI3K) and 
downregulation of Phosphatase and tensin homolog (PTEN; PI3K antagonist). Anti-
apoptotic pathways (B-cell lymphoma 2-associated X protein (Bax) /B- cell 
lymphoma 2 (Bcl-2) ratio) also appear activated. These support a mechanism of 
protection against myocardial apoptosis and necrosis. [11] 
Fourthly, CMR is the only imaging modality that is able to provide a qualitative or 
quantitative appreciation of the myocardial oedema seen in acute SC, as well as to 
examine its resolution time course during follow-up. T2-weighted images have been 
the initial investigation method in vivo for detecting acute myocardial oedema: 
multiple studies have now agreed on this one common finding in acute SC patients 
(Table 1). T1 or T2 mapping has developed as a more robust, quantifiable method, 
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being less sensitive to motion artefacts. Myocardial oedema is most likely a result of 
increased vascular and cell membrane permeability. Thus, any oedematous tissue 
corresponds to an increase in tissue water content, which is consequently reflected 
in the prolonged T1 and T2 times. The native T1 values have been found to be 
consistently increased in acute SC patients in the entire left ventricular myocardium 
compared to controls - but particularly in the apical and mid-ventricular regions, 
which are most commonly affected. [12] Unlike myocardial infarction, the oedema is 
not overlying a single vascular territory and it appears to affect the whole 
myocardium, beyond the segments affected by various degrees of dysfunction on 
cine imaging. The characteristic spontaneous recovery of the left ventricular ejection 
fraction has misled the scientific community into predicting a fast and benign 
resolution of the disease. However, subsequent studies showed that myocardial 
oedema persists for several months. Both T2-weighted semi-qualitative sequences 
as well as parametric imaging such as previously mentioned T1 mapping 
demonstrated unresolved left ventricular myocardial oedema compared to controls 3-
4 months after the acute episode. [13] Furthermore, myocardial oedema appears 
present and also persist for the same time in the right ventricular myocardium. [14] A 
recent study with follow-up extended to 5 months showed for the first time that it is 
only at this stage that the oedema begins to dissipate in the myocardium. [8] 
Supporting information has been provided from myocardial biopsy studies which 
demonstrated that the myocardial oedema may subtend an underlying inflammatory 
process. Analysis of the myocardial tissue has been performed both acutely and in 
the recovery period. A typical finding from light microscopy in the acute phase 
revealed hypertrophied myocytes and glycogen present in the cytoplasm. A net 
reduction in the glycogen content was subsequently observed a few months into 
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recovery. Moreover, localized contraction band necrosis, as well as widening of 
interstitial spaces were also observed in myocardial biopsies. Myocardial electron 
microscopy reveals numerous vacuoles with debris and myelin bodies in the acute 
phase. Sporadically, mis-shaped or mis-sized mitochondria have also been noted. 
Immunohistochemical staining revealed infiltration of neutrophils and macrophages, 
even T cells - the inflammatory response persisting up to 3 months. [15] Moreover, 
immunohistological studies have revealed an increased presence of 3-nitrotyrosine 
(3-NT) and poly-ADP ribose (PAR) in the diseased myocardium from deceased SC 
patients. These have been linked to nitrosative stress and could be a possible 
explanation for the energy depletion and negative inotropy representative in the 
pathology of the cardiomyopathy. [16] While the biopsies have the potential to 
highlight specific features of SC, setting key differences from other forms of acute 
heart failure (e.g. in myocarditis lymphocytic infiltrate predominates) became the next 
challenge.  
However, human post-mortem biopsies from patients who demised shortly after the 
onset (first 5 days) demonstrated clusters of CD68+ cells, suggesting that 
aggregates of macrophages accumulate in these patients’ hearts. Although these 
data were restricted to unfortunate, fatal cases, the insight provided was substantial 
as such examinations provided information from a much larger myocardial territory 
relative to that arising from a biopsy. [17] Although there are limitations in 
extrapolating pathophysiology similarities form an animal model of SC 
cardiomyopathy, further insight has been gained from a time course assessment of 
the experimental model.  An experimental Takotsubo rodent model suggests that the 
catecholamine-induced SC-like cardiac dysfunction culminates with the M1 polarised 
macrophages infiltration (proinflammatory). This subtype is specialised in extra-
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cellular matrix degradation and release of proinflammatory mediators. In contrast to 
MI cases, a transition towards M2 macrophages (anti-inflammatory) is not apparent. 
[17]. This was also observed in the few post-mortem human myocardial sections 
examined, however, it raised a further question: is this myocardial infiltrate present 
only in the patients who died or is it a general characteristic of the disease in all 
takotsubo patients? 
To this end, ultra-small superparamagnetic particles of iron-oxide (USPIO) enhanced 
CMR has recapitulated, non-invasively, the presence of macrophage infiltration 
within the myocardial tissue of all takotsubo patients. [8] USPIO uptake has been 
used in this case to highlight the presence of activated/phagocytic macrophages in 
the myocardium, serving as an imaging biomarker of inflammation. Thus, USPIO 
uptake irrefutably proves a macrophage-mediated intracardiac inflammation in all 
acute SC cases, not just in a few post-mortem examples which could have 
represented extreme situations that resulted in fatality. The macrophage infiltrate is 
present acutely in both ballooning and non-ballooning LV segments and becomes 
attenuated at 5 months after acute presentation. The USPIO uptake does not only 
explain for the first time at a large scale the substrate of the global myocardial 
oedema, but it also provides a contrast to other types of heart failure presentations 




The presence of global myocardial oedema alongside the macrophage infiltrates 
further suggested that systemic inflammation might play a pivotal role in the 
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pathology of the disease. Acute phase proteins (specifically C - reactive protein) and 
stretch markers (N terminal-prohormone brain natriuretic peptide – NT-pro BNP) 
have been first tested given the myocardial oedema in SC. They were both found to 
be considerably elevated, supporting the notion that systemic inflammation is 
involved in the pathological process. Interestingly, considering that much less 
myocardial injury/necrosis occurs in SC, CRP levels are comparable to ST-elevation 
myocardial infraction (STEMI) patients and showed an upward trend after admission.  
This suggests that this might be a distinct phenomenon and does not necessarily 
follow the patterns of cellular injury and death. Compared to ST-elevation MI, the 
cardiac troponins and Creatine Kinase-Muscle Bound isotype are consistently lower, 
yet BNP levels were considerably elevated, by three to four-fold. [18] These findings 
have directed researchers into proposing a unique biomarker as the NT- 
proBNP/cardiac troponin T ratio. This ratio distinguishes SC from STEMI with a 91% 
sensitivity and 95% specificity. [19] Elevated CRP and BNP also bear prognostic 
importance: cardiac complications and even in-hospital mortality were associated 
with increased serum presence of both above-mentioned proteins. It is therefore 
likely that elevated NT-proBNP and BNP levels in SC have a dual significance, both 
inflammatory and myocardial stretch being causative, but the former probably having 
a predominant role. Supporting the inflammatory role is the fact that the 
concentration of BNP/ NT-proBNP remains borderline elevated at a 3-month follow-
up. In addition, strong correlations between NT-proBNP, normetanephrine 
concentration and the severity of the disease (left ventricular ejection fraction) have 
been demonstrated. [20]  
It has been postulated that BNP could have a protective effect against reactive 
oxygen species damage, improving the hemodynamic imbalance by acting as a 
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second messenger in the cGMP pathway. The outcome of BNP release has been 
linked to limiting intra-cardiac inflammation by inhibiting the neutrophil burst and the 
subsequent reactive oxygen species formation, while at the same time avoiding the 
risks of NO release (mainly nitrosative stress). Nonetheless, there is not enough 
supporting evidence for a possible protective mechanistic role for BNP.  
NO has the capacity to bind to the superoxide anion (O2-) leading to the formation of 
peroxynitrite anion (ONOO-). As a result, redox stress, protein nitration and 
deoxyribonucleic acid damage are induced. In SC, release of NO is usually 
increased, while asymmetric dimethylarginine, a competitive NO inhibitor, is 
consistently decreased. [21] It has been postulated that a catecholamine “storm”, 
followed by β2-adrenoreceptor coupling in the detriment of β1-adrenoreceptors could 
be a mechanistic pathway in this disease. [22] This work has suggested that biased 
post-receptor signalling, leading to predominantly Gi-based stimulation in response 
to large concentrations of catecholamines, contributes towards the peri-apical 
negative inotropic changes typically seen in SC.This assertion was supported by the 
finding that blockade of Gi-based signalling by pertussis toxin prevented such 
changes. On the other hand administration of beta-adrenoceptor antagonists caused 
immediate death in this model, suggesting that this form of acute treatment should 
not be contemplated. It is also important to reiterate that the distribution of beta-
adrenergic receptors has never been explored in a human heart, therefore firm 
translation to the human condition remains a limitation. 
Although this has only been demonstrated in an experimental model and not 
replicated in the human disease, the context of nitrosative stress could further 
explain the activation of nitric oxidase synthase, hence the increased NO production. 
Experimental data showed accumulation of 3-NT and PAR in the myocardium, most 
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pronouncedly in the apical region, and these latter findings have been replicated in a 
human post-mortem series. [23] Moreover, SC patients demonstrate an aberrant 
response to NO, both in an acute setting and at a 3 months follow-up. The NO over-
responsiveness has also been positively correlated to the severity of the disease. 
[21] Sodium nitroprusside (SNP), an index of platelet NO signaling, was linked to the 
peak NT-pro BNP serum concentration, suggesting the inflammatory component that 
NO might play a role in the illness. Interestingly, while the extent of the NO pathway 
up-regulation is related to the initial myocardial damage, it has also been shown to 
be a predictor of rapid recovery. Hydrogen sulphide (H2S) potentiates NO effects by 
further activation of the soluble guanyl cyclase. Additionally, H2S limits nitrosative 
stress via degradation of cysteine and glutathione. In an experimental rodent model, 
the concentration of H2S was found to be decreased, while administration of 
exogenous H2S had a beneficial effect by limiting the myocardial oxidative injury. 
[24] Another biochemical process noticed in SC is glycocalyx shedding. This is a 
marker of endothelial dysfunction, as well as the shear stress possibly encountered 
in the pathology. However, the only microvascular abnormality confirmed focuses 
solely on the coronary arteries. [25] The sequence of events that generates this 
process remains still unknown. It could be that the glycocalyx shedding is a primary 
phenomenon, as a result of catecholamine release and subsequent neutrophil burst. 
In this scenario, the myocardial inflammation could be a result of the vascular 
damage. Conversely, it might be a secondary alteration stimulated via BNP-
mediated inflammation. Quantitively, this process can be measured by Syndecan-1 
(SD-1) in plasma, the most prevalent proteoglycan. Acutely SC patients have 
presented with a similar SD-1 level to AMI, significantly increased in comparison to 
controls, which normalised after three months. [26] Interestingly, the shedding of 
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glycocalyx could perhaps explain the hypotension often co-occurring in SC patients, 
especially as the degree of hypotension is not correlated to the lowered LVEF level. 
Likewise, matrix metallo-proteinases (MMP’s) drastically influence the release of 
glycocalyx. Recently, it has been demonstrated that an atypical MMP profile is 
present in SC patients in that collagenase-subtypes of MMPs were largely 
decreased: MMP1 by 40% and MMP8 by 60%. [27] This does not only suggest a 
tendency to preserve collagen extracellularly, and thus a pro-fibrotic state, but also 
confirms an increase shedding of SD-1. [23] As a result of the oxidative stress-
induced DNA damage, Poly [ADP-ribose] polymerase 1 (PARP-1, a first responder 
to DNA damage, facilitating DNA repair pathway choice) is activated. [28] 
Consequently, the energy impairment and lowered phosphocreatine levels could be 
explained. Moreover, the peroxynitrite anion stimulates the expression of α-arrestin 
thioredoxin-interacting protein (TXNIP), a proinflammatory mediator involved in 
protein ubiquitination and endocytosis. TXNIP levels were analysed in a rat model 
and have been found elevated by 2.5 fold in SC-induced rodents compared to 
controls, with a significant apex-base gradient. TXNIP is associated with a turbulent 
blood flow, while also reinforcing the importance of shear stress in the disease. An 
accentuating factor of the abrupt increase of TXNIP, following the ISO 
administration, could be defined by the limitation of NO’s protective effect. [23] 
Despite systemic inflammation in SC only receiving attention in the recent years, the 
first indication of its importance was signaled in a case report by Sato in 2005. 
Further associations were then raised between the cardiomyopathy and microscopic 
polyangiitis, a type of inflammatory vasculitis. [29] In the case presented anti-
inflammatory therapy (methylprednisolone) was administered with remarkable results 
noticed, particularly in limiting the cardiac damage. Clearly the treatment would have 
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suppressed the production of pro-inflammatory cytokines which have since been 
linked to the magnitude of the disease. This case report is yet equivocal in terms of 
management of SC patients, while randomised controlled trials have not been 
carried out. While many therapeutic targets have been postulated, the development 
of a precise treatment strategy remains premature until a better understanding of the 
pathophysiological processes is demonstrated. 
Recently various cytokines have been evaluated for prognostic purposes. The 
research efforts have mainly focused on IL-6 (pro-inflammatory marker) and IL-10 
(anti-inflammatory marker). IL-6 has proven to be significantly increased in AMI 
patients and has been now correlated with the rate of adverse effects in SC. The 
cytokine hypothesis has proposed that IL-6 induces muscle wasting and prompts 
heart failure. [30] IL-10 has been associated with negative cardiac remodeling. If 
both IL-6 and IL-10 are raised upon admission, the risk of adverse effects has been 
estimated to 67%, whereas if neither show a substantial increase the risk is lowered 
to 14%. [31] IL-6 and IL-10 have also illustrated a positive correlation with CRP 
levels. Additionally, several other inflammatory markers have been found elevated in 
SC patients, respectively: IL-7 (interestingly, even at higher levels compared with 
AMI patients; this cytokine has been linked to the development of atherosclerotic 
plaques), growth regulated protein and chemokine ligand 1 (chemoattractant for 
neutrophils). [32] 
Growth differentiation factor-15 (GDF-15) is a cytokine belonging to transforming 
growth factor β family. It was shown to be released during stress-induced damage by 
cardiomyocytes and vascular smooth muscle cells and has been used for risk 
stratification in acute coronary syndrome patients. Stiermaier et al has illustrated that 
SC patients present with significantly increased GDF-15 compared to STEMI 
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controls. Moreover, biventricular ballooning was a predictor factor for an elevated 
GDF-15. [33] 
The cytokine surge and oedema also prompt the release of carbohydrate-antigen-
125 (CA-125) from pericardial cells. It has been positively correlated with NT-proBNP 
and is inversely proportional to the LVEF upon admission. CA-125 has been used as 
both a short-term and long-term prognostic tool for adverse outcomes and length of 
hospitalisation period. [34] 
The innate immune system activation is also highlighted via the changes in white 
blood cell count. Both total white cell and neutrophil count were significantly elevated 
acutely (p<0.001 compared with controls). Furthermore, monocyte subpopulations 
during the acute episode have shown notable alterations in a recently published 
study of our research group [8]. While the total monocyte count has shown no 
significant difference compared to controls, in the 0-3 days period after admission, a 
significant increase in the number of classical monocytes (CD14++CD16-, Mon1) to 
the detriment of intermediate (CD14++CD16+, Mon2) and non-classical 
(CD14+CD16++, Mon3) monocytes has been recorded. [8] Mon 1 are recruited in 
the acute inflammatory phase, accumulating in the injured areas of the myocardium 
and causing further inflammation by degrading proteins. It can be further 
hypothesised that the macrophage activity detected is a result of migration of Mon1 
cells into the myocardium, rather than a proliferative effect of the already existent 
tissue resident macrophages. Moreover, Mon2 concentration remains decreased for 
a sustained period of time, in opposition to the process taking place in acute 
myocardial infraction: A change towards the Mon3 monocytes is noticed in the 
weeks following an MI, thus limiting the pro-healing inflammatory processes. The 
sustained low concentration of Mon2 could therefore explain the unresolved 
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myocardial inflammation in SC. The consistent increase over a period of 5 months in 
IL-8 and chemokine (C-X-C motif) ligand 1 (CXCL1), has been related to monocyte 
adhesion, as well as macrophage infiltration in the myocardium. In the TERRIFIC 
trial, in the acute setting, the mean concentration of IL-8 was 45.5±8.62 (n=55) and 
increased over a period of 5 months to 61.9±10.28 (n=48). The value reached 
clinical significance (p=0.009) compared to matched control subjects 21.7±10.86 (n= 
51) at the 5 month follow-up. [8] Even more interestingly, the HEROIC trial analysed 
the serum cytokine profile at a median time of 20 months from the onset of the acute 
episode, thus analysing the longer-term inflammatory profile of the disease. An 
increased trend in the expression of CXCL1 in the patients with prior SC was again 
noticed compared to controls (p=0.08). This finding further describes the specific 
clinical phenotype of SC in the recovery stage, respectively heart failure that 
presents in conjuncture with a low-grade, cytokine-mediated, systemic inflammatory 
state. [35] 
 
Other studies have also revealed increased activation in the pro-thrombotic 
pathways, in SC patients compared to healthy controls, while the results were 
comparable to acute myocardial infraction (AMI) patients. This explains the relatively 
high (9.9%) per patient-year risk of cardiac and cerebrovascular events. [36] 
Fitzgibbons et al tested 1,310 serum proteins in patients suffering from SC in 
comparison to AMI patients and controls. The upregulation of proteins was noticed 
mainly in the coagulation pathway and complement cascade. Only 6 proteins have 
been expressed differently solely in SC versus controls: complement 3, factor V, 
Follistatin Like 3 (increases adhesion of blood cells to fibronectin; inhibits TGF-β 
signaling), Netrin-1 (upregulates endothelial NO production), PLAT and THBS2 
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(matrix metalloproteinases secretion). [37] These proteins could become alternative 
cardiac biomarkers specific to SC.  
There are several other biomarkers which have been proposed for the early 
detection of SC. First off, Micro-RNAs have also been studied in regard to their 
effectiveness as possible cardiac biomarkers. A signature profile of micro-RNA has 
been created for SC, respectively: increased miR1, miR16, miR26a and miR133a. 
[38] MiR1 and MiR133a are indicators of cardiac damage, whereas both miR16 and 
miR26a have been linked to stress and reduced cardiac contractility. Moreover, miR-
371a-5p has been shown to have a slight correlation to the disease. It controls the 
regulation of Bcl2 associated anthogene 3 (BAG3). [39] BAG3 orchestrates the 
chaperone-assisted autophagy pathway, inhibiting apoptotic mechanisms via 
removal of faulty proteins. At least a mutation of this gene is present in 72.9% of SC 
patients, compared to 46.9% in the control population. However, the presented study 
only compared SC patients with healthy female controls and did not present other 
cardiac conditions in comparison.  BAG3 has recently emerged as a key myocytic 
homeostatic control, being mutated in a wide variety of heart failure complexes. [40] 
Therefore the specificity of BAG3 and miR-371a-5p is limiting the clinical application 
of the results. Mi1-25a-5p was seen in unusual quantities in the plasma, suggesting 
a surge in endothelin-1. However, it is yet to be elucidated whether the 
microvascular impairment is an independent phenomenon, or a result of the 
extravascular obstruction caused by oedema. [37] Importantly, the results on Micro-
RNAs and genetic profiling currently do not have enough supporting information to 
be considered for their diagnostic utility. Secondly, serum copeptin was also 
analysed as a possible cardiac biomarker. As a vasopressin prohormone, which is 
released as result of a stressor event, it has been found to be highly elevated in SC. 
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[41] This has only been reported in an isolated incident and therefore needs a more 
rigorous study design to reach a conclusion concerning its efficiency.  
DRAWING PARALLELS WITH OTHER CARDIAC INFLAMMATORY 
CONDITIONS  
While SC has been reported in association to a wide range of other diseases and co-
morbidities, a great density of cases has focused on the correlation between it and 
inflammation-mediated conditions, such as: septicemia, anaphylaxis, Kounis 
syndrome, hemophagocytic lymphohistiocytosis. This was expected given that 
mononuclear cells appear to play a vital role in the development of the illness. 
Interestingly, sepsis is a major triggering factor for SC, some reports identifying it as 
the single most important contributor. [42, 43] The mechanisms that induce SC in 
this scenario could rely on cytokine toxicity, particularly Tumour necrosis factor-α 
and IL-1β, impeding the cardiac contractility. Theoretically, anaphylactoid reaction 
could induce SC via similar mechanisms to sepsis. Anaphylaxis in the setting of SC 
is particularly challenging, since exogenous catecholamines could further worsen the 
cardiac dysfunction. Several case reports have associated hemophagocytic 
lymphohistiocytosis (HLH) with SC. [44, 45] HLH is described by multi-organ damage 
as a result of an acute systemic inflammation. In HLH, the activated macrophages 
and histocytes phagocytise other blood cells. HLH causes organ dysfunction mainly 
via cytokine storms. Another disease SC has been compared to is Kounis syndrome 
(or allergic myocardial infraction). Type I is the most common form of the disease, 
resulting in coronary spasm as a consequence of an exposure to an allergen despite 
otherwise unobstructed coronary arteries. Since both diseases are prompted by 
similar inflammatory mediators, cases have been reported where the illnesses 
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appeared in conjunction. [46] This correlation could dictate a direction for future 
research, perhaps in establishing the relation between inflammatory mediators and 
SC. 
FUTURE RESEARCH AND CONTROVERSIES 
Current advancements reveal more dilemmas concerning the pathological processes 
underlying SC.  It is clear that inflammation is an integral part of the disease, but the 
cause-effect relationship remains unknown. It could be that the inflammation in this 
disease is a secondary phenomenon, perhaps precipitated by autonomic 
imbalance/overdrive or micro-vascular abnormalities, or conversely the inflammatory 
process being causative in the course of SC, driving the microcirculatory 
abnormalities through a mechanical, compressing effect of oedema for example. 
It is imperative to continue probing on the mechanism of the disease. The 
hypotheses formulated so far, respectively: the catecholamine surge, sympathetic 
overdrive, multi-vessel epicardial spasms, microvascular dysfunction, and 
inflammation, have failed to fully explain the evolution of this complex syndrome. The 
postulated proposals do not reciprocally exclude each other, while the typical 
phenotype could be a result of their synergistic action. Understanding the 
mechanistic pathways is the cornerstone to elucidating the most effective therapeutic 
actions. 
As the pathophysiology of SC remains largely elusive, no international guidelines in 
terms of treatment have reached consensus. Given the current knowledge of the 
disease, it is safe to assume that administration of exogenous catecholamines 
should be avoided, at least until further clarification. Retrospective studies have 
indicated that beta-blockers are not effective in the reduction of in-hospital mortality 
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or recurrence rate. Anti-inflammatory agents have been suggested to act as future 
therapeutic targets. Nonetheless, there is still a lot to be investigated before 
randomised control trials with a correspondent evidence-based therapeutic 
management could be performed. Otherwise, in the case of complications 
(cardiogenic shock/ cardiac arrhythmias) the standard pharmacological or 
mechanical support is usually recommended. 
Furthermore, there is an urgent need for more pertinent cardiac biomarkers, ideally 
to distinguish it rapidly as clinical phenocopy of myocardial infarction. Several 
markers of inflammation, ventricular stretch and gene expression have shown a 
significant correlation to the disease (BNP: troponin/myoglobin, microRNA, 
cytokines, copeptin). Despite constant progress, search, as to which biomarker 
should be used, continues.  
 
 
Table 1- The results of T2-weighted images in relation to myocardial oedema in SC 
Study Myocardial 
oedema (acutely) 
LGE detected Other findings 
2009, Abdel-Aty 
et al [47] 
100%(7/7) - * Minute foci of 
intramural LE 
(14.29%) 






elevated T2 ratio 




2009, Rolf et al 
[49] 
100% (15/15) 33.3% (5/15) - 
2011, Eitel et al 
[50] 




2012, Neil et al 
[13] 






et al [51] 




*LGE not attempted  




Table 2- Concentration of IL- 6 at admission of patients suffering from SC 










2019, C. Scally 
et al [35] 
23±7 (29) 18±10 0.7 
2018, C. Scally 
et al [8] 
23.1 ± 4.54 (55)  6.5±5.83  <0.001 
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2018, F. Santoro 
et al [52] 
12.37±17.48 (32) 25.42±27.71* 0.03 
2016, F. Santoro 
et al [31] 
41.25±136 (56) - - 
2011, R. Pirzer 
et al [32] 




* Control subjects suffered from acute coronary syndrome 
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